Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Remifentanil
Hospital Authority, Hong Kong
Labor Pain
1 trial -
Revefenacin
Theravance Biopharma Ireland Umited
Chronic Obstructive Pulmonary Disease
1 trial -
Sufentanil
The First People's Hospital of Lianyungang
Arteriovenous Malformation
1 trial -
Sugammadex hameln 100 mg/ml oplossing voor injectie, Naloxon HCl Accord 0,4 mg/ml, oplossing voor injectie / infusie in een voorgevulde spuit, ANEXATE 0,5 mg/5 ml, solution injectable (I.V.), REMIMAZOLAM , Sufentanil Viatris 5 microgram/ml oplossing voor injectie, Esmeron 10 mg/ml, oplossing voor injectie
Disc Medicine
General anesthesia
1 trial -
TAMOXIFEN
Disc Medicine
Breast cancer
1 trial -
Tenofovir Alafenamide 25 MG
The First People's Hospital of Lianyungang
Chronic Hepatitis C
1 trial -
Tenofovir Alafenamide Tablets
The First People's Hospital of Lianyungang
Chronic Hepatitis b
1 trial -
Tenofovir Alafenamide fumarate 25mg Oral Tablet
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chronic Hepatitis B
1 trial -
Thoracic epidural (ropivicaine, fentanyl)
BRIGHT MINDS BIOSCIENCES INC.
Pectus Excavatum
1 trial -
Urapidil Accord 5 mg/ml solución inyectable y para perfusión EFG, Trandate 5mg/ml Solution for Injection, Fenilefrina Altan 0,1 mg/ml solución inyectable y para perfusión.
The George Institute
Acute Ischemic Stroke
1 trial -
VERAPAMIL , NEBIVOLOL , PROPAFENONE , BISOPROLOL , AMIODARONE , FLECAINIDE , SOTALOL , DILTIAZEM
Pari Pharma GmbH
Asymptomatic Patients with frequent PVCs and normal LVEF
1 trial -
Vemurafenib
Hoffmann-La Roche
Neoplasms
1 trial -
dabrafenib
Novartis Pharmaceuticals
Melanoma
1 trial -
diclofenac sodium topical gel
Teva Pharma GmbH
Multiple Sclerosis
1 trial -
hydrochloride hydromorphone + flurbiprofen axetil
The First People's Hospital of Lianyungang
Enhanced Recovery After Surgery
1 trial -
intravenous sufentanil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Analgesia, Patient-Controlled
1 trial -
mycophenolate mofetil (Myfenax)
Teva Pharma GmbH
Stable Renal Transplant Recipients
1 trial -
0.1% bromfenac ophthalmic solution
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cataract
1 trial -
100mg diclofenac
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Post-ERCP Acute Pancreatitis
1 trial -
Bupivacaine / fentaNYL
Grace Therapeutics
Depression, Postpartum
1 trial -
Cytoxan
shifeng Lou
Hemophagocytic Syndrome
1 trial -
Dexmedetomidine Injection (nasal spray) + Propofol Injection + Sufentanil Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Dexmedetomidine Induced Sedation
1 trial -
Diclofenac
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Esketamine, Sulfentanil or/and Remifentanil
Second Affiliated Hospital of Soochow University
Opioid Analgesic Adverse Reaction
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources